Joshua Hundert, MD
Nephrology · Dorchester, MANPI 1679732317
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $194,398 of the $229,209 with a category attached, or 84.8%. Bayer accounts for 88.9% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $95,355, more than ten times the $213 reported in 2019. Among nephrology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 291 payments — averaging $787.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$204K
- Novo Nordisk$13K
- Akebia Therapeutics Inc$7K
- Calliditas Therapeutics US Inc.$4K
- Nxstage Medical, Inc.$279
- Amgen$218
- plus $812 from 12 others
What the payments were for
- Consulting fees$7,7203%
- Speaking & faculty fees$194,39885%
- Travel & lodging$19,3718%
- Food & beverage$7,5883%
- Education$1320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 193 | $203,801 |
| Novo Nordisk | 15 | $12,720 |
| Akebia Therapeutics Inc | 18 | $7,310 |
| Calliditas Therapeutics US Inc. | 5 | $4,070 |
| Nxstage Medical, Inc. | 6 | $279 |
| Amgen | 10 | $218 |
| Otsuka America Pharmaceutical, Inc. | 6 | $208 |
| Mallinckrodt Hospital Products Inc. | 1 | $150 |
| Novartis | 7 | $148 |
| Travere Therapeutics, Inc. | 20 | $89 |
| Boehringer Ingelheim | 2 | $43 |
| AstraZeneca | 2 | $41 |
| Baxter Healthcare | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Vifor Pharma, Inc. | 1 | $25 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| Ardelyx, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$201,175
- Ozempic$12,459
- Vafseo$6,929
- TARPEYO$4,000
- TERLIVAZ$150
- JYNARQUE$122
- PUREFLOW SL$115
- NXSTAGE SYSTEM ONE$115
How this compares
$229,209 in reported general payments places this provider in the 95th percentile of 339 nephrology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 40 | $135,856 |
| LokelmaSodium Zirconium Cyclosilicate | 94 | $97,163 |
| OzempicSemaglutide | 84 | $82,115 |
| KerendiaFinerenone | 63 | $77,117 |
| AuryxiaFerric Citrate | 35 | $63,361 |
| JardianceEmpagliflozin | 64 | $62,075 |
| MounjaroTirzepatide | 49 | $52,285 |
| TrulicityDulaglutide | 39 | $44,365 |
| FarxigaDapagliflozin Propanediol | 49 | $38,606 |
| Sevelamer Carbonate | 127 | $25,678 |
| EliquisApixaban | 13 | $15,547 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $11,249 |
| Torsemide | 313 | $7,614 |
| Calcitriol | 88 | $2,368 |
| Losartan Potassium | 214 | $2,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLokelma, Farxiga | $41 | $135,769143 claims |
| Lilly USA, LLCMounjaro, Trulicity | $18 | $96,65088 claims |
| Novo NordiskOzempic | $12,720 | $82,11584 claims |
| BayerKerendia | $203,801 | $77,11763 claims |
| Akebia Therapeutics IncAuryxia | $7,310 | $63,36135 claims |
| Boehringer IngelheimJardiance | $43 | $62,07564 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 339 nephrology providers in Massachusetts.
Other nephrology in Dorchester
- David FriedmanBoston$19.8M
- Martin PollakBoston$19.8M
- Dennis AusielloBoston$4.6M
- Ajay SinghBoston$916K
- Michael GermainSpringfield$443K
- Rekha AbichandaniCambridge$442K
- Leslie FangBoston$388K
- Nicolaos AthienitesBrockton$294K
- Jean FrancisBoston$244K
- Joseph BonventreBoston$175K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.